艾塞利斯制药

US · EXEL #1156 按市值排名上市于 1970

62.23 -0.60 -0.96%

实时 - 追踪5344个代码 - 心跳于121秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

增持

最近一期（2026/Q3）披露持股的机构数量减少了4家。
机构持股总比例上升了0.6个百分点。

机构持股

机构持股比例: 106.31% +0.60pp
机构数量: 882 -4
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund70.95%

Hedge Fund23.69%

Public Company4.34%

Government Pension Fund2.92%

Individual/Insider2.63%

Private Company2.12%

Sovereign Wealth Fund1.09%

Insurance Company0.65%

Family Office/Trust0.34%

主要股东截至 2026-06-30

BlackRock 11.73% · 29.08M 股

Farallon Capital Management, L.L.C. 5.65% · 13.99M 股

Renaissance Technologies Corp. 5.42% · 13.43M 股

Vanguard Capital Management, LLC 5.06% · 12.54M 股

Vanguard Portfolio Management, LLC 4.86% · 12.04M 股

AQR Capital Management 4.42% · 10.94M 股

State Street Global Advisors 4.02% · 9.97M 股

Fuller & Thaler Asset Management, Inc. 3.60% · 8.93M 股

LSV Asset Management 3.29% · 8.15M 股

Geode Capital Management, LLC 3.09% · 7.65M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 17次买入 · 33次卖出

姓名	职务	持股比例
Michael Morrissey	Chief Executive Officer	1.37%
Stelios Papadopoulos	Co-Founder & Independent Chair of the Board	0.48%
Christopher Senner	Chief Financial Officer	0.22%
Patrick Haley	Executive Vice President of Commercial	0.14%
Jack Wyszomierski	Independent Director	0.11%
Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	0.10%
Jeffrey Hessekiel	General Counsel	0.08%
George Poste	Independent Director	0.05%
Maria Freire	Independent Director	0.04%
Tomas Heyman	Independent Director	0.01%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-09	Mary Beckerle	Director	Automatic Disposition	-9,812	$53.66
2026-05-31	Jack Wyszomierski	Independent Director	Automatic Disposition	-3,925	$50.55
2026-05-31	Sue Eckhardt	Director	Automatic Disposition	-9,812	$50.14
2026-05-26	Jack Wyszomierski	Independent Director	Other Acquisition	+8,367	--
2026-05-26	Stelios Papadopoulos	Co-Founder & Independent Chair of the Board	Other Acquisition	+8,367	--
2026-05-26	George Poste	Independent Director	Other Acquisition	+8,367	--
2026-05-26	Sue Eckhardt	Director	Other Acquisition	+8,367	--
2026-05-26	Mary Beckerle	Director	Other Acquisition	+8,367	--
2026-05-26	Julie Smith	Independent Director	Other Acquisition	+8,367	--
2026-05-26	Maria Freire	Independent Director	Other Acquisition	+8,367	--
2026-05-26	Robert Oliver	Independent Director	Other Acquisition	+8,367	--
2026-05-26	Tomas Heyman	Independent Director	Other Acquisition	+8,367	--
2026-05-26	David Johnson	Independent Director	Other Derivative Acquisition	+19,133	$50.03
2026-05-25	Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	Intent to Sell (Form 144)	-43,451	$50.35
2026-05-19	Patrick Haley	Executive Vice President of Commercial	Open Market Disposition	-32,110	$49.81
2026-05-17	Michael Morrissey	Chief Executive Officer	Other Acquisition	+124,047	--
2026-05-17	Michael Morrissey	Chief Executive Officer	Other Disposition	-124,047	--
2026-05-17	Christopher Senner	Chief Financial Officer	Open Market Disposition	-34,901	$50.00
2026-05-17	Brenda Hefti	General Counsel	Automatic Disposition	-6,625	$50.21
2026-05-14	Michael Morrissey	Chief Executive Officer	Sale to Issuer	-128,497	$51.10

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。